Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201309035 Principal Investigator: Lockhart, A. Craig
Title: Phase II study of FOLFIRINOX chemotherapy for treatment of advanced gastric, gastro-esophageal junction, and esophageal tumors
Description: The purpose of this research study is to look at the safety and effectiveness of a 4-drug regimen called FOLFIRINOX when being used to treat gastric and esophageal cancer....MORE
___________________________________________________________________________________________________
 Number: 201102254 Principal Investigator: Edmundowicz, Steven
Title: Endoscopic Resection or Ablation for Patients with Dysplasia or Intramucosal Cancer Requiring Treatment of Barrett’s Esophagus: the ERADICATE trial A Multi-Center Randomized Controlled Trial
Description: This is a multi-center prospective, RCT conducted at 4 centers. 82 patients with HGD and/or EC who meet the study criteria will be enrolled, undergo a baseline diagnostic EMR and then be randomized in a 1:1 ratio to undergo treatment by either stepwise endoscopic mucosal resection (S-EMR) or radiofr...MORE
___________________________________________________________________________________________________
 Number: RTOG 1010 Principal Investigator: Robinson, Clifford
Title: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma
Description: This study is being done to compare the effects, good and/or bad, of the addition of trastuzumab to standard chemotherapy, radiation, and surgery for patients with HER2 positive esophageal cancer....MORE
___________________________________________________________________________________________________
 Number: CALGB 80803 Principal Investigator: Lockhart, A. Craig
Title: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Description: The purpose of this trial is to learn if we can improve the outcomes for patients with esophageal cancer by using PET/CT scans to determine whether or not a particular chemotherapy regimen is showing any effect on the tumor. We are trying to learn if PET/CT response can be used as a way to better di...MORE
___________________________________________________________________________________________________
 Number: 201212078 Principal Investigator: Lockhart, A. Craig
Title: Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
Description: The purpose of this study is to evaluate how well MM-111 controls esophageal, gastroesophageal, or gastric cancer that expresses a protein called HER2 when given in combination with standard treatment (paclitaxel and trastuzumab)....MORE
___________________________________________________________________________________________________
 Number: 201204145 Principal Investigator: Meyers, Bryan
Title: Photoacoustic Endoscopy of Barrett's Esophagus: A Pilot Study
___________________________________________________________________________________________________
 Number: 201205189 Principal Investigator: Mullady, Daniel
Title: Predicting Stage and Severity of Esophageal Adenocarcinoma using a Dysphagia Symptom Questionnaire
___________________________________________________________________________________________________
 Number: 201101765 Principal Investigator: Puri, Varun
Title: Prospective Collection of health Information and Biospecimens in Esophageal Cancer
___________________________________________________________________________________________________
 Number: 201209045 Principal Investigator: Kushnir, Vladimir
Title: Outcomes following Endoscopic Therapy for Early Stage Esophageal Cancer
___________________________________________________________________________________________________
 Number: 201108327 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE
___________________________________________________________________________________________________
 Number: 201107068 Principal Investigator: Lockhart, A. Craig
Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment
Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE
___________________________________________________________________________________________________